The impact of G protein-coupled oestrogen receptor 1 on male breast cancer: a retrospective analysis.
GPER-1
GPR30
MBC
OS
RFS
male breast cancer
survival analysis
Journal
Contemporary oncology (Poznan, Poland)
ISSN: 1428-2526
Titre abrégé: Contemp Oncol (Pozn)
Pays: Poland
ID NLM: 101233223
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
09
2021
accepted:
23
09
2021
entrez:
3
11
2021
pubmed:
4
11
2021
medline:
4
11
2021
Statut:
ppublish
Résumé
The G protein-coupled oestrogen receptor 1 (GPER-1) is a potential prognostic marker in breast cancer. However, its role in male breast cancer (MBC) is still unknown. This study evaluates the expression of GPER-1 in MBC samples and correlates these data with clinical and pathological parameters including patients' survival. For this retrospective analysis of a prospectively maintained cohort of patients with MBC, we examined 161 specimens for GPER-1 expression using immunohistochemistry. An immunoreactive score (IRS) was calculated based on staining intensity and the percentage of positive tumour cells. Then, we correlated GPER-1 IRS with clinical and pathological parameters, and overall and relapse-free survival. About 40% of MBC samples were positive for GPER-1 expression (IRS ≥ 4). There was no significant correlation with clinicopathological parameters, such as hormone receptor status or grading. However, a statistical trend was observed for tumour size (≥ 2 cm, We found no significant prognostic value of GPER-1 in this MBC cohort as anticipated from studies on female BC. Future studies with higher sample size are needed to further verify a potential sex-specific role of GPER-1.
Identifiants
pubmed: 34729041
doi: 10.5114/wo.2021.110010
pii: 45435
pmc: PMC8547179
doi:
Types de publication
Journal Article
Langues
eng
Pagination
204-212Informations de copyright
Copyright © 2021 Termedia.
Références
Arch Gynecol Obstet. 2020 Feb;301(2):565-571
pubmed: 31900584
PLoS One. 2020 Apr 17;15(4):e0231786
pubmed: 32302351
J Cancer Res Clin Oncol. 2014 May;140(5):713-23
pubmed: 24553912
Crit Rev Oncol Hematol. 2017 May;113:283-291
pubmed: 28427518
Br J Cancer. 2020 Jul;123(1):33-37
pubmed: 32367072
Ann Oncol. 2013 Jun;24(6):1434-43
pubmed: 23425944
PLoS One. 2014 Jan 08;9(1):e83296
pubmed: 24421881
J Cancer Res Clin Oncol. 2014 Apr;140(4):663-71
pubmed: 24515910
Genomics. 1997 Nov 1;45(3):607-17
pubmed: 9367686
Breast Cancer Res. 2013 Nov 29;15(6):R114
pubmed: 24289103
CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26
pubmed: 12568441
J Nucl Med. 2021 May 10;62(5):605-611
pubmed: 33579807
J Cancer Res Clin Oncol. 2018 Feb;144(2):381-387
pubmed: 29204896
Oncologist. 2015 Jun;20(6):586-92
pubmed: 25948676
Clin Breast Cancer. 2014 Feb;14(1):31-9
pubmed: 24220158
Br J Cancer. 2019 Feb;120(3):301-305
pubmed: 30655614
Am J Obstet Gynecol. 2010 Dec;203(6):595.e9-16
pubmed: 20965484
J Clin Oncol. 2010 Apr 20;28(12):2114-22
pubmed: 20308661
Breast Cancer Res Treat. 2013 Jan;137(2):465-70
pubmed: 23224235
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Breast Cancer Res Treat. 2011 Jul;128(2):457-66
pubmed: 21607586
Clin Cancer Res. 2006 Nov 1;12(21):6359-66
pubmed: 17085646
J Cancer Res Clin Oncol. 2020 Dec;146(12):3175-3188
pubmed: 32813115
J Natl Cancer Inst. 1994 Jun 1;86(11):829-35
pubmed: 8182763
Breast Cancer Res Treat. 2014 May;145(1):61-71
pubmed: 24715381
Breast Cancer Res Treat. 2020 Apr;180(2):471-479
pubmed: 32040687
Clin Cancer Res. 2013 Apr 1;19(7):1681-92
pubmed: 23554355
Endocrine. 2010 Aug;38(1):29-37
pubmed: 20960099
Annu Rev Physiol. 2008;70:165-90
pubmed: 18271749
Carcinogenesis. 2015 May;36(5):564-73
pubmed: 25823895
Oncol Rep. 2010 Nov;24(5):1115-20
pubmed: 20878100
N Engl J Med. 2018 Jun 14;378(24):2311-2320
pubmed: 29897847
Breast Cancer Res Treat. 2019 Feb;174(1):121-127
pubmed: 30478785
Biomolecules. 2019 Sep 18;9(9):
pubmed: 31540491
Front Endocrinol (Lausanne). 2014 May 06;5:66
pubmed: 24834064
Cancer. 1998 Nov 1;83(9):1947-55
pubmed: 9806653
J Cancer Res Clin Oncol. 2018 Jan;144(1):13-19
pubmed: 28924735